|Bid||41.55 x 900|
|Ask||55.86 x 800|
|Day's Range||55.32 - 56.65|
|52 Week Range||32.47 - 58.93|
|Beta (5Y Monthly)||1.64|
|PE Ratio (TTM)||2.43|
|Earnings Date||Jul 28, 2021 - Aug 02, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.88|
Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) is possibly approaching a major achievement in its business, so we would...
Agios (AGIO) incurs wider-than-expected loss in the first quarter of 2021. The company fails to record revenues due to the sale of its oncology portfolio including Tibsovo.
Please be advised that this call is being recorded at Agios' request. With me on the call today with prepared remarks are Dr. Jackie Fouse, our Chief Executive Officer; Dr. Chris Bowden, our Chief Medical Officer; Daren Miles, our Chief Commercial Officer; and Jonathan Biller, our Chief Financial Officer and Head of Legal and Corporate Affairs.